MedTrace Logo

Plasma Appearance of Xanthohumol in Healthy Adults

NCT05524714 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-11-22

No results posted yet for this study

Summary

The aim of this study is to investigate the rate and extend of the plasma appearance of native Xanthohumol and Xanthohumol integrated into micelles in healthy men and women. Therefore, participants consume capsules with either 86 or 172 mg of native Xanthohumol or Xanthohumol integrated into micelles. In an observation period of 24 hours, Xanthohumol and its major metabolites are analyzed in plasma.

Conditions

  • Plasmakinetics of Xanthohumol

Interventions

DIETARY_SUPPLEMENT

solubilized Xanthohumol low dose

single administration of 2 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol and 2 soft gelatine capsules containing only micelles

DIETARY_SUPPLEMENT

solubilized Xanthohumol high dose

single administration of 4 soft gelatine capsules each containing 43 mg micellar solubilized Xanthohumol

DIETARY_SUPPLEMENT

native Xanthohumol low dose

single administration of 2 hard gelatine capsules each containing 43 mg native Xanthohumol and 2 hard gelatine capsules containing silicon dioxide

DIETARY_SUPPLEMENT

native Xanthohumol high dose

single administration of 4 hard gelatine capsules each containing 43 mg native Xanthohumol

Sponsors & Collaborators

  • University of Hohenheim

    collaborator OTHER

  • University of Bonn

    lead OTHER

Principal Investigators

  • Sarah Egert, Prof PhD · University of Bonn

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-01
Primary Completion
2023-03-03
Completion
2023-03-03

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05524714 on ClinicalTrials.gov